SAN FRANCISCO (GenomeWeb) – Natera plans to make use of its ability to analyze fetal fraction when running its noninvasive prenatal test to add extra value to its current test and to develop new reproductive health products, the company said this week.
Get the full story with
GenomeWeb Premium Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.